Abstract
Normal controls (NC) (n=15), patients with panic disorder (PD) (n=13) and patients with major depression (MD) (n=17) were challenged with a single, oral dose (0.25 mg/kg) of the selective 5HT agonist m-chlorophenyl-piperazine (MCPP) or placebo. Blood samples were assayed for cortisol and MCPP levels every 30 min. The PD group had an augmented cortisol release when compared to the other two groups. Finally, a significant correlation was found across all subjects between clinical anxiety level and cortisol release on MCPP. These data support the hypothesis of 5HT receptor hypersensitivity in PD.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Carr DB, Sheehan DV, Surman OS, Coleman JH, Greenblatt DJ, Heninger GR, Jones KJ, Levin PH, Watkins WD (1986) Neuroendocrine correlates of lactate-induced anxiety and their response to chronic alprazolam therapy. Am J Psychiatry 143:483–494
Ceulemans DLS, Hoppenbrouwers MLJA, Gelders YG, Reyntjens AJM (1985) The influence of ritanserin, a serotonin antagonist, in anxiety disorders: a double-blind placebo-controlled study versus lorazepam. Pharmacopsychiatry 18:303–305
Charney DS, Heninger GM (1985) Increased anxiogenic effects of caffeine in panic disorder. Arch Gen Psychiatry 42:233–243
Charney DS, Woods SW, Goodman WK, Heninger GR (1987) Serotonin function in anxiety. II. Effects of the serotonin agonist MCPP in panic disorder patients and healthy subjects. Psychopharmacology 92:14–24
Endicott F, Spitzer RL (1978) A diagnostic interview: the schedule for affective disorders and schizophrenia. Arch Gen Psychiatry 35:837–844
Fuller RW, Snoddy HD, Mason NR, Owen JE (1981) Disposition and pharmacological effects of m-chlorophenylpiperazine in rats. Neuropharmacology 20:155–162
Goldberg MR, Jackson RV, Krakau J (1986) Influence of yohimbine on release of anterior pituitary hormones. Life Sci 39:395–398
Goodwin GM, Green AR (1985) A behavioral and biochemical study in mice and rats of putative selective agonists and antagonists for 5HT1 and 5HT2 receptors. Br J Pharmacol 84:743–753
Gorman JM, Liebowitz MR, Fyer AJ, Goetz D, Campeas RB, Fyer MR, Davies SO, Klein DF (1987) An open trial of fluoxetine in the treatment of panic attacks. J Clin Psychopharmacol 7:329–332
Kahn RS, Westenberg HGM (1985) 1–5-Hydroxytryptophan in the treatment of anxiety disorders. J Affective Disord 8:197–200
Kahn RS, Westenberg HGM, Verhoeven WMA, Gispen-de Wied CC, Kamerbeek WDJ (1987) Effect of a serotonin precursor and uptake inhibitor in anxiety disorders; a double-blind comparison of 5-hydroxytryptophan, clomipramine and placebo. Int Clin Psychopharmacol 2:33–41
Kahn RS, van Praag HM, Wetzler S, Asnis GM, Barr G (1988a) Serotonin and anxiety revisited. Biol Psychiatry 23:189–208
Kahn RS, Wetzler S, Asnis GM, Strauman T, van Praag HM (1988b) Indication of serotonergic supersensitivity in panic disorder. Psychiatr Res (in press)
Liebowitz MR, Gorman JM, Fyere AJ, Levitt M, Dillon D, Levy G, Appleby IC, Anderson S, Palij M, Davies SO (1985) Lactate provocation of panic attacks. Biochemical and physiological findings. Arch Gen Psychiatry 42:709–719
Liebowitz MR, Gorman JM, Fyer A, Dillon D, Levitt M, Klein DF (1986) Possible mechanisms for lactate's induction of panic. Am J Psychiatry 143:495–502
McNair DM, Lorr M, Droppelman LF (1971) Manual for the Profile of Mood States, Educational and Industrial testing Service, San Diego, California
Montgomery SA, Asberg M (1979) A new depression scale desgned to be sensitive to change. Br J Psychiatry 134:382–389
Mueller EA, Sunderland T, Murphy DL (1985) Neuroendocrine effects of m-CPP, a serotonin agonist, in humans. J Clin Endocrinol Metab 61(6):1179–1184
Mueller EA, Murphy DL, Sunderland T (1986) Further studies of the putative serotonin agonist, m-chlorophenylpiperazine: evidence for a serotonin receptor mediated mechanism of action in humans. Psychopharmacology 89:388–391
Peroutka SJ (1986) Selective labeling of 5HT1a and 5HT1b binding sites in bovine brain. Brain Res 344:167–171
Snaith RP, Baugh SJ, Clayden AD (1982) The clinical anxiety scale: an instrument derived from the Hamilton anxiety scale. Br J Psychiatry 141:518–524
Spitzer RL, Endicott J, Robins E (1978) Research diagnostic criteria: rationale and reliability. Arch Gen Psychiatry 35:773–782
Taylor DP, Eison MS, Riblet LA, Vandermaelen CP (1985) Pharmacological and clinical effects of buspirone. Pharmacol Biochem Behav 23:687–694
Trulson ME, Arasteh K (1985) Buspirone decreases the activity of 5-hydroxytryptamine-containing dorsal raphe neurons in vitro. J Pharm Pharmacol 38:380–382
van Praag HM, Lemus CZ, Kahn RS (1987) Hormonal probes of central serotonergic activity: do they really exist? Biol Psychiatry 22:86–98
Wilkinson L (1986) Manual for Systat. Systat, Inc., Evanston Illinois
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kahn, R.S., Asnis, G.M., Wetzler, S. et al. Neuroendocrine evidence for serotonin receptor hypersensitivity in panic disorder. Psychopharmacology 96, 360–364 (1988). https://doi.org/10.1007/BF00216062
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00216062